Cybin Inc. Common Stock
HELP
Rang in Aktien
#11599
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Aktienkurs
$10.30
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$638.32M
Veränderung (1 Tag)
2.88%
Veränderung (1 Jahr)
9,119.52%
Land
CA
Handel Cybin Inc. Common Stock (HELP)
Kategorie
Healthcare
Kursverlauf für Cybin Inc. Common Stock (HELP)
Höchster Schlusskurs: $0.12 am 2023-10-01
Niedrigster Schlusskurs: $0.40 am 2021-06-01
Niedrigster Schlusskurs: $0.40 am 2021-06-01
Kursverlauf der Aktie von Cybin Inc. Common Stock von 2021 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2023 | 81.70% |
| 2022 | -76.32% |
| 2021 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.44 | -4.05% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
